Anticoagulation Therapy with Apixaban
Introduction to Apixaban
- The American College of Cardiology recommends apixaban as a highly effective and safe anticoagulant compared to warfarin and other direct oral anticoagulants (DOACs) for most patients requiring anticoagulation 1, 2
Contraindications and Precautions
- Apixaban should not be used in patients with mechanical heart valves, moderate to severe mitral stenosis, or severe hepatic impairment 1, 2, 3
- Exercise caution when using apixaban in patients with antiphospholipid syndrome, as vitamin K antagonists are preferred 4
- Exercise caution when using apixaban in patients with active cancer and luminal GI malignancies, as low molecular weight heparin (LMWH) may be considered instead 5
Comparison to Warfarin
- Apixaban has a lower risk of intracranial hemorrhage and no routine coagulation monitoring is required compared to warfarin 1, 2
- Apixaban has fewer drug-drug interactions, fixed dosing, and no dietary restrictions compared to warfarin 1, 2
Dosing and Administration
- No specific dosing information is available with associated citations, however, standard dosing for nonvalvular atrial fibrillation is typically 5 mg twice daily for most patients, with reduced dose of 2.5 mg twice daily for patients with certain characteristics, such as age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL
Special Considerations
- For patients with severe renal impairment, the 2.5 mg twice daily dose is recommended to minimize bleeding risk 3
Procedures and Bridging
- No bridging anticoagulation is typically needed when stopping apixaban for procedures, with stop times of 24 hours for low bleeding risk and 48 hours for high bleeding risk procedures
Common Errors to Avoid
- Failing to adjust dose in elderly patients, those with low body weight, or renal impairment
- Inappropriate co-administration with other anticoagulants or antiplatelet agents
- Not considering drug interactions that may affect apixaban levels
- Abrupt discontinuation without appropriate bridging or transition to another anticoagulant